SARS-CoV-2 Antibody Neutralization Assay Platforms Based on Epitopes Sources: Live Virus, Pseudovirus, and Recombinant S Glycoprotein RBD

Septisetyani, Endah Puji; Prasetyaningrum, Pekik Wiji; Anam, Khairul; Santoso, Adi

doi:10.4110/in.2021.21.e39

Cited by 8 publications

(11 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pseudoviruses are a type of recombinant viral particle whose backbone and envelope proteins are derived from different viruses [ 38 ]. Genes of the viral vector are typically modified so that they are unable to produce their own surface protein, which is then replaced with the surface glycoprotein of the designated virus [ 39 , 40 ]. The producing pseudoviruses can infect host cells but replicate intracellularly for only a single cycle [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

Development and characterization of an antibody that recognizes influenza virus N1 neuraminidases

Chen,

Wang,

Zhu

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Influenza A viruses (IAVs) continue to pose a huge threat to public health, and their prevention and treatment remain major international issues. Neuraminidase (NA) is the second most abundant surface glycoprotein on influenza viruses, and antibodies to NA have been shown to be effective against influenza infection. In this study, we generated a monoclonal antibody (mAb), named FNA1, directed toward N1 NAs. FNA1 reacted with H1N1 and H5N1 NA, but failed to react with the NA proteins of H3N2 and H7N9. In vitro, FNA1 displayed potent antiviral activity that mediated both NA inhibition (NI) and blocking of pseudovirus release. Moreover, residues 219, 254, 358, and 388 in the NA protein were critical for FNA1 binding to H1N1 NA. However, further validation is necessary to confirm whether FNA1 mAb is indeed a good inhibitor against NA for application against H1N1 and H5N1 viruses.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and characterization of an antibody that recognizes influenza virus N1 neuraminidases

Chen,

Wang,

Zhu

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…However, this test requires the handling of an SARS-CoV-2 replication-competent virus in a BSL3 laboratory facility by well-trained staff and is time-consuming. 39 , 40 Pseudotyped-virus-based assays require BSL-2 conditions, but this method is not suitable for high-throughput screening (HTS) and cannot be rapidly adapted to upcoming variants. 41 , 42 Therefore, neutralization assays that are suitable for HTS without the use of infectious virus preparation are still needed.…”

Section: Discussionmentioning

confidence: 99%

tANCHOR-cell-based assay for monitoring of SARS-CoV-2 neutralizing antibodies rapidly adaptive to various receptor-binding domains

Ivanusic,

Maier,

Icli

et al. 2024

iScience

View full text Add to dashboard Cite

“…A fundamental goal of serology testing is to understand the extent to which an individual is protected from further infection. Because neutralization assays are essential for determining the infection rate, predicted humoral protection, as well as vaccine efficacy during clinical trials and after large-scale vaccination, the different platforms of neutralization assays, including MN, pvNT, and surrogate assay, have been developed [30]. An increasing body of literature supports the neutralization assay and the clinical outcome.…”

Section: Correlates Of Protection (Cops)mentioning

confidence: 99%

Monoclonal Antibodies as SARS-CoV-2 Serology Standards: Experimental Validation and Broader Implications for Correlates of Protection

Wang,

Patrone,

Kearsley

et al. 2023

IJMS

View full text Add to dashboard Cite

COVID-19 has highlighted challenges in the measurement quality and comparability of serological binding and neutralization assays. Due to many different assay formats and reagents, these measurements are known to be highly variable with large uncertainties. The development of the WHO international standard (WHO IS) and other pool standards have facilitated assay comparability through normalization to a common material but does not provide assay harmonization nor uncertainty quantification. In this paper, we present the results from an interlaboratory study that led to the development of (1) a novel hierarchy of data analyses based on the thermodynamics of antibody binding and (2) a modeling framework that quantifies the probability of neutralization potential for a given binding measurement. Importantly, we introduced a precise, mathematical definition of harmonization that separates the sources of quantitative uncertainties, some of which can be corrected to enable, for the first time, assay comparability. Both the theory and experimental data confirmed that mAbs and WHO IS performed identically as a primary standard for establishing traceability and bridging across different assay platforms. The metrological anchoring of complex serological binding and neuralization assays and fast turn-around production of an mAb reference control can enable the unprecedented comparability and traceability of serological binding assay results for new variants of SARS-CoV-2 and immune responses to other viruses.

show abstract

SARS-CoV-2 Antibody Neutralization Assay Platforms Based on Epitopes Sources: Live Virus, Pseudovirus, and Recombinant S Glycoprotein RBD

Cited by 8 publications

References 88 publications

Development and characterization of an antibody that recognizes influenza virus N1 neuraminidases

Development and characterization of an antibody that recognizes influenza virus N1 neuraminidases

tANCHOR-cell-based assay for monitoring of SARS-CoV-2 neutralizing antibodies rapidly adaptive to various receptor-binding domains

Monoclonal Antibodies as SARS-CoV-2 Serology Standards: Experimental Validation and Broader Implications for Correlates of Protection

Contact Info

Product

Resources

About